SPRO and GSK Related Headlines
Go Back- FDA approves GSK and Spero's oral carbapenem antibiotic Utebzi
- Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
- Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
- GSK receives FDA approval for oral antibiotic to treat UTIs
- Spero and GSK report positive phase 3 trial for oral antibiotic
- PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
SPRO and GSK Related Press Releases
Go Back- Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
- Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
- PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
